EHA Library - The official digital education library of European Hematology Association (EHA)

A COHORT OF 22 PATIENTS WITH SAMD9/SAMD9L DISORDER: BONE MARROW FAILURE AND MDS PREDISPOSITION WITH TRANSIENT MONOSOMY 7
Author(s): ,
Marie Sébert
Affiliations:
Laboratoire d'hématologie, U944 ,IUH (Hôpital St Louis),Paris,France
,
Olivier Bluteau
Affiliations:
Laboratoire d'hématologie, U944 ,IUH (Hôpital St Louis),Paris,France
,
Thierry Leblanc
Affiliations:
Service d'Hématologie pédiatrique,Hôpital Robert-Debré,Paris,France
,
Anna Raimbault
Affiliations:
Laboratoire d'hématologie, U944 ,IUH (Hôpital St Louis),Paris,France
,
Régis Peffault De Latour
Affiliations:
Hématologie-greffe,Hôpital Saint-Louis (AP-HP),Paris,France
,
Samuel Quentin
Affiliations:
Laboratoire d'hématologie, U944 ,IUH (Hôpital St Louis),Paris,France
,
Elodie Lainey
Affiliations:
Service d'hématologie biologique,Hôpital Robert-Debré,Paris,France
,
Lucie Hernandez
Affiliations:
Laboratoire d'hématologie, U944 ,IUH (Hôpital St Louis),Paris,France
,
Jean-Hugues Dalle
Affiliations:
Service d'hématologie et immunologie pédiatrique,Hôpital Robert-Debré,Paris,France
,
Flore Sicre de Fontebrune
Affiliations:
Hématologie-greffe,Hôpital Saint-Louis (AP-HP),Paris,France
,
Emanuelle Clappier
Affiliations:
Laboratoire d'hématologie, U944 ,IUH (Hôpital St Louis),Paris,France
,
Nicolas Boissel
Affiliations:
Hématologie AJA,Hôpital Saint-Louis,Paris,France
,
Claudine Schmitt
Affiliations:
Hématologie pédiatrique,C.H.U. de Nancy,Nancy,France
,
Marc Muller
Affiliations:
Hématologie pédiatrique,C.H.U. de Nancy,Nancy,France
,
Nicolas Blin
Affiliations:
Hématologie clinique,CHU Hôtel-Dieu, Place Alexis-Ricordeau,Nantes,France
,
Benedicte Bruno
Affiliations:
Hématologie pédiatrique,Hôpital Jeanne de Flandre,Lille,France
,
Isabelle Pellier
Affiliations:
Service des maladies du sang,C.H.U. d'Angers,Paris,France
,
Arnaud Petit
Affiliations:
Service d'hématologie et oncologie pédiatrique,Hôpital d'enfants Armand Trousseau,Paris,France
,
Stephane Blanche
Affiliations:
Service d'hématologie-immunologie et rhumatologie pédiatrique,Hôpital Universitaire Necker-Enfants Malades,Paris,France
,
Guy Leverger
Affiliations:
Service d'hématologie et oncologie pédiatrique,Hôpital d'enfants Armand Trousseau,Paris,France
,
Gerard Michel
Affiliations:
Service d'hématologie et oncologie pédiatrique,Hôpital de la Timone,Marseille,France
,
Yves Bertrand
Affiliations:
Service d'hématologie et immunologie pédiatrique,Institut d'Hématologie et d'Oncologie Pédiatrique,Lyon,France
,
André Baruchel
Affiliations:
Service d'Hématologie pédiatrique,Hôpital Robert-Debré,Paris,France
,
Gérard Socié
Affiliations:
Hématologie-greffe,Hôpital Saint-Louis (AP-HP),Paris,France
Jean Soulier
Affiliations:
Laboratoire d'hématologie, U944 ,IUH (Hôpital St Louis),Paris,France
(Abstract release date: 05/17/18) EHA Library. Sébert M. 06/17/18; 214622; S1580
Marie Sébert
Marie Sébert
Contributions
Abstract

Abstract: S1580

Type: Oral Presentation

Presentation during EHA23: On Sunday, June 17, 2018 from 08:00 - 08:15

Location: Room A8

Background

SAMD9L and SAMD9 are two genes located at chromosome 7q21 that encode for two large homologous proteins implicated in inflammatory and antiviral responses. While these genes can be lost somatically in myelodysplastic syndromes (MDS) (Nagamachi, Cancer Cell 2013), germline activating mutations have been recently associated to the autosomal dominant syndromes Ataxia-Pancytopenia (SAMD9L gene; Chen, Am J Hum Genet 2016) and MIRAGE (SAMD9 gene; MDS, infection, restriction of growth, adrenal hypoplasia, genital phenotypes, and enteropathy; Narumi, Nat Genet 2016). We and other have found that SAMD9 and SAMD9L germline heterozygous mutations further defined a spectrum of bone marrow failure (BMF) and MDS genetic predisposition in children (Tesi, Blood 2017; Bluteau, Blood 2017; Schwartz, Nat com 2017).

Aims

In order to delineate better the SAMD9/SAMD9L associated disorder, we analyzed a cohort of 22 patients (pts) with germline SAMD9 or SAMD9L mutations originating from 16 families.

Methods

Patients and relatives were originally investigated in the laboratory of the French Aplasia Center to search for a familial origin to their BMF or MDS. All subjects gave informed consent for genetic investigation, tissue banking and research, and this study was IRB approved. We here report the natural clinical history of 22 patients, with a median FU of 6 years (7 months-37y). In 14 of them, we analysed hematopoietic somatic events using WES and Sanger re-sequencing on blood or bone marrow samples, in comparison with fibroblast DNA.

Results

Fifteen and 7 pts with SAMD9L and SAMD9 germline mutations were identified, from 9 and 7 unrelated families, with a median age at first hematological signs of 13 months (8 months-46y) and 7 years (2-21y), respectively. Six out of 15 SAMD9L pts had neurological signs and 1/7 SAMD9 pts had a MIRAGE syndrome. Immunoglobulin deficiency with recurrent infections was found in both SAMD9 (N=4/7) and in SAMD9L (N=3/15) pts. Regarding hematological features, 20 pts had central cytopenia, with BM dysplasia in 11 and monosomy 7 in 10. Except one with an additional TERC germline mutation, patients did not present excess of blasts or cytogenetic lesion in addition to monosomy 7 at any point of their natural history. Ten had a family history while 12 presented simplex. Strikingly, spontaneous improvement in blood cell counts was seen in 11 pts, and MDS and monosomy 7 disappearance in 5 pts, with a median follow-up of 4 y. HSCT that was planned for five of these pts was eventually cancelled and they are still alive without consistent cytopenia with a follow-up of four to 33 years. Finally, two carrier subjects had no overt hematological signs. We sequenced blood and/or marrow mononuclear cells in 14 pts and found somatic changes such as acquired 7q uniparental disomy (UPD) or additional SAMD9 or SAMD9L cis-mutations in 7 of them, suggesting spontaneous genetic correction of the germline mutated allele.

Conclusion

Germline mutations of SAMD9 and SAMD9L delineate an inherited BMF/MDS predisposition disorder in children and young adults with frequent transient monosomy 7. Patients may benefit from a careful watch-and-wait policy rather than upfront HSCT, even when presenting with dysplasia and monosomy 7, a practice-changing option that will have to be carefully evaluated.

Session topic: 11. Bone marrow failure syndromes incl. PNH – Biology & Translational Research

Keyword(s): Bone Marrow Failure, MDS

Abstract: S1580

Type: Oral Presentation

Presentation during EHA23: On Sunday, June 17, 2018 from 08:00 - 08:15

Location: Room A8

Background

SAMD9L and SAMD9 are two genes located at chromosome 7q21 that encode for two large homologous proteins implicated in inflammatory and antiviral responses. While these genes can be lost somatically in myelodysplastic syndromes (MDS) (Nagamachi, Cancer Cell 2013), germline activating mutations have been recently associated to the autosomal dominant syndromes Ataxia-Pancytopenia (SAMD9L gene; Chen, Am J Hum Genet 2016) and MIRAGE (SAMD9 gene; MDS, infection, restriction of growth, adrenal hypoplasia, genital phenotypes, and enteropathy; Narumi, Nat Genet 2016). We and other have found that SAMD9 and SAMD9L germline heterozygous mutations further defined a spectrum of bone marrow failure (BMF) and MDS genetic predisposition in children (Tesi, Blood 2017; Bluteau, Blood 2017; Schwartz, Nat com 2017).

Aims

In order to delineate better the SAMD9/SAMD9L associated disorder, we analyzed a cohort of 22 patients (pts) with germline SAMD9 or SAMD9L mutations originating from 16 families.

Methods

Patients and relatives were originally investigated in the laboratory of the French Aplasia Center to search for a familial origin to their BMF or MDS. All subjects gave informed consent for genetic investigation, tissue banking and research, and this study was IRB approved. We here report the natural clinical history of 22 patients, with a median FU of 6 years (7 months-37y). In 14 of them, we analysed hematopoietic somatic events using WES and Sanger re-sequencing on blood or bone marrow samples, in comparison with fibroblast DNA.

Results

Fifteen and 7 pts with SAMD9L and SAMD9 germline mutations were identified, from 9 and 7 unrelated families, with a median age at first hematological signs of 13 months (8 months-46y) and 7 years (2-21y), respectively. Six out of 15 SAMD9L pts had neurological signs and 1/7 SAMD9 pts had a MIRAGE syndrome. Immunoglobulin deficiency with recurrent infections was found in both SAMD9 (N=4/7) and in SAMD9L (N=3/15) pts. Regarding hematological features, 20 pts had central cytopenia, with BM dysplasia in 11 and monosomy 7 in 10. Except one with an additional TERC germline mutation, patients did not present excess of blasts or cytogenetic lesion in addition to monosomy 7 at any point of their natural history. Ten had a family history while 12 presented simplex. Strikingly, spontaneous improvement in blood cell counts was seen in 11 pts, and MDS and monosomy 7 disappearance in 5 pts, with a median follow-up of 4 y. HSCT that was planned for five of these pts was eventually cancelled and they are still alive without consistent cytopenia with a follow-up of four to 33 years. Finally, two carrier subjects had no overt hematological signs. We sequenced blood and/or marrow mononuclear cells in 14 pts and found somatic changes such as acquired 7q uniparental disomy (UPD) or additional SAMD9 or SAMD9L cis-mutations in 7 of them, suggesting spontaneous genetic correction of the germline mutated allele.

Conclusion

Germline mutations of SAMD9 and SAMD9L delineate an inherited BMF/MDS predisposition disorder in children and young adults with frequent transient monosomy 7. Patients may benefit from a careful watch-and-wait policy rather than upfront HSCT, even when presenting with dysplasia and monosomy 7, a practice-changing option that will have to be carefully evaluated.

Session topic: 11. Bone marrow failure syndromes incl. PNH – Biology & Translational Research

Keyword(s): Bone Marrow Failure, MDS

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies